Abstract
Background & Aims: Noninvasive assessment of liver stiffness has been increasingly used to evaluate fibrosis instead of liver biopsy, especially in patients with chronic viral hepatitis. The aim of this study was to assess the performance in staging liver fibrosis of the updated ElastPQ® technique (EPIQ7 ultrasound system, Philips Healthcare, Bothell, WA, USA) in the “real life” setting by using the FibroScan as the reference standard and to understand whether the use of the quality criteria improves the performance of the technique. Methods: This was a cross-sectional study: 278 patients affected by chronic hepatitis C referred for liver stiffness measurement with the FibroScan® 502 Touch device (Echosens, Paris, France) underwent measurements also with the ElastPQ® technique. For the assessment of significant fibrosis (F≥2), advanced fibrosis (F≥3) and cirrhosis (F=4), respectively, we used the cutoffs of 7.0, 9.5 and 12.0 kPa. The diagnostic performance of ElastPQ® was assessed using the area under the ROC (AUROC) curve analysis and was evaluated overall and for cases with (a) 10 measurements and IQR/M≤30%, (b) 5 measurements and IQR/M ≤30%, (c) 10 measurements and IQR/M>30%, (d) 5 measurements and IQR/M>30%. Results: The optimal cutoffs of ElastPQ® for significant fibrosis, advanced fibrosis and cirrhosis were 6.43, 9.54 and 11.34 kPa, respectively. For measurements with an IQR/M≤30%, there was no statistically significant decrease in sensitivity between 10 and 5 measurements (p=0.26, p=0.09, p=0.71, for F≥2, F≥3, and F=4, respectively). Conclusion: The ElastPQ® technique is reliable and accurate for staging liver fibrosis. The number of measurements does not affect the performance.
| Original language | English |
|---|---|
| Pages (from-to) | 331-335 |
| Number of pages | 5 |
| Journal | Journal of Gastrointestinal and Liver Diseases |
| Volume | 25 |
| Issue number | 3 |
| Publication status | Published - Sep 1 2016 |
Fingerprint
Keywords
- Chronic hepatitis C
- Liver cirrhosis
- Liver stiffness
- Shear wave elastography
- Transient elastography
ASJC Scopus subject areas
- Gastroenterology
Cite this
Accuracy of the ElastPQ® technique for the assessment of liver fibrosis in patients with chronic hepatitis C : A “real life” single center study. / Ferraioli, Giovanna; Maiocchi, Laura; Lissandrin, Raffaella; Tinelli, Carmine; De Silvestri, Annalisa; Filice, Carlo; Above, Elisabetta; Barbarini, Giorgio; Bruno, Raffaele; Corona, Silvia; Dellafior, Carolina; Di Gregorio, Marta; Gulminetti, Roberto; Lanzarini, Paolo; Ludovisi, Serena; Malfitano, Antonello; Maserati, Renato; Michelone, Giuseppe; Minoli, Lorenzo; Mondelli, Mario; Novati, Stefano; Patruno, Savino F A; Poma, Gianluigi; Sacchi, Paolo; Zanaboni, Domenico; Liver Fibrosis Study Group.
In: Journal of Gastrointestinal and Liver Diseases, Vol. 25, No. 3, 01.09.2016, p. 331-335.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Accuracy of the ElastPQ® technique for the assessment of liver fibrosis in patients with chronic hepatitis C
T2 - A “real life” single center study
AU - Ferraioli, Giovanna
AU - Maiocchi, Laura
AU - Lissandrin, Raffaella
AU - Tinelli, Carmine
AU - De Silvestri, Annalisa
AU - Filice, Carlo
AU - Above, Elisabetta
AU - Barbarini, Giorgio
AU - Bruno, Raffaele
AU - Corona, Silvia
AU - Dellafior, Carolina
AU - Di Gregorio, Marta
AU - Gulminetti, Roberto
AU - Lanzarini, Paolo
AU - Ludovisi, Serena
AU - Malfitano, Antonello
AU - Maserati, Renato
AU - Michelone, Giuseppe
AU - Minoli, Lorenzo
AU - Mondelli, Mario
AU - Novati, Stefano
AU - Patruno, Savino F A
AU - Poma, Gianluigi
AU - Sacchi, Paolo
AU - Zanaboni, Domenico
AU - Liver Fibrosis Study Group
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background & Aims: Noninvasive assessment of liver stiffness has been increasingly used to evaluate fibrosis instead of liver biopsy, especially in patients with chronic viral hepatitis. The aim of this study was to assess the performance in staging liver fibrosis of the updated ElastPQ® technique (EPIQ7 ultrasound system, Philips Healthcare, Bothell, WA, USA) in the “real life” setting by using the FibroScan as the reference standard and to understand whether the use of the quality criteria improves the performance of the technique. Methods: This was a cross-sectional study: 278 patients affected by chronic hepatitis C referred for liver stiffness measurement with the FibroScan® 502 Touch device (Echosens, Paris, France) underwent measurements also with the ElastPQ® technique. For the assessment of significant fibrosis (F≥2), advanced fibrosis (F≥3) and cirrhosis (F=4), respectively, we used the cutoffs of 7.0, 9.5 and 12.0 kPa. The diagnostic performance of ElastPQ® was assessed using the area under the ROC (AUROC) curve analysis and was evaluated overall and for cases with (a) 10 measurements and IQR/M≤30%, (b) 5 measurements and IQR/M ≤30%, (c) 10 measurements and IQR/M>30%, (d) 5 measurements and IQR/M>30%. Results: The optimal cutoffs of ElastPQ® for significant fibrosis, advanced fibrosis and cirrhosis were 6.43, 9.54 and 11.34 kPa, respectively. For measurements with an IQR/M≤30%, there was no statistically significant decrease in sensitivity between 10 and 5 measurements (p=0.26, p=0.09, p=0.71, for F≥2, F≥3, and F=4, respectively). Conclusion: The ElastPQ® technique is reliable and accurate for staging liver fibrosis. The number of measurements does not affect the performance.
AB - Background & Aims: Noninvasive assessment of liver stiffness has been increasingly used to evaluate fibrosis instead of liver biopsy, especially in patients with chronic viral hepatitis. The aim of this study was to assess the performance in staging liver fibrosis of the updated ElastPQ® technique (EPIQ7 ultrasound system, Philips Healthcare, Bothell, WA, USA) in the “real life” setting by using the FibroScan as the reference standard and to understand whether the use of the quality criteria improves the performance of the technique. Methods: This was a cross-sectional study: 278 patients affected by chronic hepatitis C referred for liver stiffness measurement with the FibroScan® 502 Touch device (Echosens, Paris, France) underwent measurements also with the ElastPQ® technique. For the assessment of significant fibrosis (F≥2), advanced fibrosis (F≥3) and cirrhosis (F=4), respectively, we used the cutoffs of 7.0, 9.5 and 12.0 kPa. The diagnostic performance of ElastPQ® was assessed using the area under the ROC (AUROC) curve analysis and was evaluated overall and for cases with (a) 10 measurements and IQR/M≤30%, (b) 5 measurements and IQR/M ≤30%, (c) 10 measurements and IQR/M>30%, (d) 5 measurements and IQR/M>30%. Results: The optimal cutoffs of ElastPQ® for significant fibrosis, advanced fibrosis and cirrhosis were 6.43, 9.54 and 11.34 kPa, respectively. For measurements with an IQR/M≤30%, there was no statistically significant decrease in sensitivity between 10 and 5 measurements (p=0.26, p=0.09, p=0.71, for F≥2, F≥3, and F=4, respectively). Conclusion: The ElastPQ® technique is reliable and accurate for staging liver fibrosis. The number of measurements does not affect the performance.
KW - Chronic hepatitis C
KW - Liver cirrhosis
KW - Liver stiffness
KW - Shear wave elastography
KW - Transient elastography
UR - http://www.scopus.com/inward/record.url?scp=84986188600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986188600&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84986188600
VL - 25
SP - 331
EP - 335
JO - Journal of Gastrointestinal and Liver Diseases
JF - Journal of Gastrointestinal and Liver Diseases
SN - 1841-8724
IS - 3
ER -